Omnicell (NASDAQ:OMCL) Issues Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.150-0.250 for the period, compared to the consensus earnings per share estimate of 0.310. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $264.9 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Trading Up 1.2 %

Shares of OMCL opened at $44.38 on Thursday. Omnicell has a one year low of $25.12 and a one year high of $55.74. The stock has a 50 day moving average price of $44.60 and a 200 day moving average price of $43.22.

Analyst Upgrades and Downgrades

Several analysts have recently commented on OMCL shares. Craig Hallum lifted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. upped their price target on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Omnicell presently has an average rating of “Hold” and an average target price of $52.33.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.